A 55-year-old man from Mumbai presents with painless cervical lymphadenopathy and hepatosplenomegaly. Biopsy shows diffuse infiltration of large atypical B lymphocytes with CD5+ immunophenotype. Which single feature best distinguishes this diagnosis (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) from Mantle Cell Lymphoma?

## Distinguishing CLL/SLL from Mantle Cell Lymphoma ### Clinical Context Both CLL/SLL and mantle cell lymphoma present with lymphadenopathy, hepatosplenomegaly, and a CD5+ B-cell phenotype. The challenge is distinguishing them using reliable pathologic features. ### Comparative Table | Feature | CLL/SLL | Mantle Cell Lymphoma | |---------|---------|----------------------| | **CD5 expression** | Positive | Positive | | **CD23 expression** | **Positive** | **Negative** | | **Cytogenetics** | del(13q), del(11q), del(17p); NO t(11;14) | t(11;14) (95%) | | **Cyclin D1** | Normal | Overexpressed | | **Ki-67 index** | Low (<10%) | Intermediate to high (30–50%) | | **Morphology** | Small, mature lymphocytes | Small to medium cells, nodular/diffuse | | **Median survival** | 5–10 years (variable) | 3–5 years (poor prognosis) | | **Age** | Elderly (median 70 years) | Older adults (median 60 years) | ### Why CD23 Positivity is the Gold Standard Discriminator **Key Point:** The **CD5+/CD23+ immunophenotype is pathognomonic for CLL/SLL**, whereas mantle cell lymphoma is **CD5+/CD23−**. This single-parameter flow cytometry distinction is: 1. **Objective and reproducible** — flow cytometry is standardized across laboratories. 2. **Rapid** — results available within hours. 3. **Highly specific** — CD23 negativity in a CD5+ lymphoma strongly suggests mantle cell lymphoma. 4. **Part of WHO diagnostic criteria** for both entities. **High-Yield:** The mnemonic **"CLL is CD5+/CD23+; MCL is CD5+/CD23−"** is essential for rapid diagnosis. **Mnemonic:** **"CD5 is the CLOWN (CLL + Mantle Cell); CD23 is the CLUE (CLL Only)"** — CD23 distinguishes CLL from MCL. ### Pathophysiology of CD23 Expression **Clinical Pearl:** CD23 is a low-affinity IgE receptor and is upregulated by CD40-CD40L interaction and IL-4 signaling in CLL cells. In mantle cell lymphoma, the t(11;14) translocation drives cyclin D1 overexpression, which suppresses CD23 transcription, resulting in CD23 negativity. ### Why Other Features Are Not Discriminators **Warning:** - **t(11;14) and cyclin D1** are specific to mantle cell lymphoma but require FISH or immunohistochemistry — slower and more expensive than flow cytometry. - **Nodal involvement and splenomegaly** occur in both diseases. - **CD5+ and CD19+ phenotype** are shared by both CLL/SLL and mantle cell lymphoma — not discriminatory. - **Ki-67 index** is helpful but overlaps and requires quantitative assessment, less practical than CD23 flow cytometry. ### Diagnostic Algorithm ```mermaid flowchart TD A[CD5+ B-cell lymphoma]:::outcome --> B{CD23 positive?}:::decision B -->|Yes| C[CLL/SLL]:::outcome B -->|No| D{t(11;14) or cyclin D1+?}:::decision D -->|Yes| E[Mantle Cell Lymphoma]:::outcome D -->|No| F[Other lymphoma]:::outcome C --> G[Low Ki-67, indolent course]:::action E --> H[Higher Ki-67, aggressive course]:::urgent ```